Anti-Infective Drugs Advisory Committee

Food and Drug Administration Center for Drug Evaluation and Research

Parklawn Building, 5600 Fishers Lane, Conference Rooms G, H & I and Room 1066, 5630 Fishers Lane, Rockville, MD

Supplemental New Drug Applications(NDA) 19-537/S038, 19-847/S024, 19-857/S027, 19-858/S021, 20-780/S008 for Cipro® (ciprofloxacin), Bayer Corporation, Pharmaceutical Division

Agenda - July 28, 2000

8:30 Call to Order, Introductions: Barth Reller, M.D., Chair

Meeting Statement: Thomas H. Perez, M.P.H., Executive Secretary

Opening Comments: Diane Murphy, M.D., Director, ODE IV

9:00 Bayer Corporation Presentation:

Andrew S. Verderame, Associate Director, Regulatory Affairs

9:30 Anthrax clinical disease and epidemiology Martin Hugh-Jones, D.V.M.

10:00 Human pathology inhalational disease David Walker, M.D.

10:30 Non-human primate model of inhalational anthrax Arthur Friedlander, M.D.

11:10 Break

11:30 FDA Presentation: FDA's Perspective

Gary K. Chikami, M.D., Director, Division of Anti-Infective Drug Products

Andrea Meyerhoff, M.D., Medical Reviewer, Division of Special Pathogens and Immunologic Drug Products.

12:00 Lunch

1:30 Open Public Hearing

2:30 Break

2:45 Charge to the Committee, Introduction to Questions:

Discussion and Questions

5:00 Adjourn

Consultants and Guests

James W. Bayuk, M.D., Director of Environmental Health & Preventive Medicine, U.S. State Department Scott Deitchman, M.D., National Institute for Occupational Safety and Health Arthur Friedlander, M.D., U.S. Army Medical Research Institute of Infectious Diseases Martin Hugh-Jones, D.V.M., School of Veterinary Medicine, Louisiana State University Jonathan Moreno, Center for Biomedical Ethics, University of Virginia Ernest Takafuji, M.D., U.S. Army, Office of the Assistant Secretary of Defense David Walker, M.D., University of Texas Medical Branch Michael M. Wertz, Operations Officer, U.S. State Department

Open Public Hearing

Itzhak Brook, M.D., Armed Forces Radiobiologic Research Institute